0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Inhibition of Splenic Macrophage Tumor Necrosis Factor α Secretion In Vivo by Antilipopolysaccharide Monoclonal Antibodies

Richard J. Battafarano, MD; Randall S. Burd, MD; Karla M. Kurrelmeyer, MD; Craig A. Ratz; David L. Dunn, MD, PhD
Arch Surg. 1994;129(2):179-186. doi:10.1001/archsurg.1994.01420260075010.
Text Size: A A A
Published online

Objective:  This study tried to determine whether administration of antilipopolysaccharide (LPS) murine monoclonal antibody (mAb) 2A3 to mice was associated with (1) protective capacity during experimental gramnegative bacterial sepsis, and (2) inhibition of tumor necrosis factor α (TNF-α) secretion in the systemic circulation and at the tissue level during experimental infection.

Design:  Mice received an initial intravenous injection of either saline or 100 μg of anti-LPS mAb 2A3, and 1 hour later underwent intraperitoneal inoculation of viable Escherichia coli 0111:B4. Mortality was assessed daily for 7 days. Separate groups of mice were treated similarly and plasma TNF-α concentrations were determined from blood samples obtained at 1, 3, 6,10, and 16 hours after infection by enzyme-linked immunosorbent assay. Concurrently, splenocytes harvested from animals 3, 10, and 16 hours after infection were incubated in culture ex vivo and supernatant TNF-α levels were determined.

Results:  Pretreatment with anti-LPS mAb 2A3 prior to an intraperitoneal challenge of live E coli 0111:B4 was associated with the following: (1) significant protective capacity (100% vs 0% mortality, P<.001); (2) inhibition of plasma TNF-α levels 16 hours after infection (1257±323 pg/mL vs 292±254 pg/mL, P<.001); and (3) abrogation of TNF-α secretion derived from splenic macrophages isolated 16 hours after bacterial challenge (229±12 pg/mL vs 107±48 pg/mL, P<.05).

Conclusions:  These results strongly support the contention that inhibition of LPS-induced TNF-α secretion at both the tissue and systemic levels is a key mechanism by which anti-LPS mAbs provide protection during gramnegative bacterial peritonitis. We believe that in vivo monitoring of macrophage cytokine secretion will be critical for elucidating the precise role of a variety of mediators in the pathogenesis of gram-negative bacterial sepsis.(Arch Surg. 1994;129:179-186)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();